Shares of Enlivex Therapeutics Ltd (NASDAQ:ENLV) climbed nearly 16% after the company released its fourth-quarter 2025 results, supported by strong gains tied to its treasury holdings. The stock recently traded around $1.30, bringing its year-to-date return to roughly 56%.
The biotechnology company said its financial performance was significantly strengthened by the appreciation of RAIN tokens, which form part of its treasury strategy. The valuation increase helped drive a sharp rise in reported income even as the broader cryptocurrency market experienced a challenging year.
Financial performance driven by treasury assets
Enlivex reported net income of $1.23 billion for 2025, largely reflecting the revaluation of its RAIN token holdings. Treasury and treasury-related assets reached $2.31 billion, while shareholders’ equity stood at $1.93 billion.
The company reported diluted earnings per share of $25.48 for the year. However, historical data shows that over the last twelve months through the third quarter of 2025, the company had recorded diluted EPS of -$0.54, and analysts do not expect profitability in the near term.
Enlivex also highlighted its strong liquidity position, with a current ratio of 6.43, indicating that liquid assets significantly exceed short-term liabilities.
Clinical development progress
Alongside the financial update, Enlivex reported progress in its clinical pipeline. The company recently received FDA clearance to begin a Phase IIb clinical trial evaluating its therapy for osteoarthritis.
The trial is expected to generate top-line data in 2027, potentially supporting a future Phase III program targeting a large market with significant unmet medical needs.
Capital strategy and funding
Enlivex also completed several strategic capital initiatives during the year, including $21 million in debt financing, aimed at strengthening its balance sheet and supporting both treasury and clinical activities.
Management commentary
Executive Chairman Shai Novik highlighted the company’s strategy of combining biotechnology development with a treasury approach linked to prediction markets.
Chief Executive Officer Oren Hershkovitz said the company sees significant opportunity in this model, positioning Enlivex as an early mover in integrating prediction market assets within a publicly traded biotech structure.
Risks and challenges
Despite the strong treasury gains, the company faces several ongoing risks. Its long-term outlook remains closely tied to the success of its clinical programs, while volatility in cryptocurrency markets could affect the value of its treasury assets.
Regulatory approvals for future clinical trials also remain a key hurdle.
Investor questions
During the earnings call, analysts raised questions about the company’s exposure to digital asset volatility given the downturn in parts of the crypto market.
Executives responded by emphasizing the distinct positioning of prediction market tokens, arguing that the company’s strategy combines financial innovation with biotechnology development.
Enlivex said maintaining progress in both areas—treasury asset performance and clinical pipeline advancement—will be key to sustaining investor confidence going forward.